Table 5.
Subgroup analysis of TTP and OS based on tumor features
| Items | DEB-TACE | cTACE | P value |
|---|---|---|---|
| Single tumor | n = 16 | n = 23 | |
| Median TTP (95%CI), months | 6 (4.7, 7.3) | 2 (0.7, 3.3) | 0.139 |
| Median OS (95%CI), months | 14 (12.7, 15.3) | 6 (4.0, 8.0) | 0.107 |
| Multiple tumors | n = 24 | n = 26 | |
| Median TTP (95%CI), months | 4 (3.1, 4.9) | 2 (1.0, 3.0) | 0.370 |
| Median OS (95%CI), months | 9 (7.1, 10.9) | 6 (4.3, 7.7) | 0.032 |
| Lymph node metastasis | n = 31 | n = 29 | |
| Median TTP (95%CI), months | 4 (2.0, 6.0) | 3 (2.1, 3.9) | 0.497 |
| Median OS (95%CI), months | 9 (4.6, 13.4) | 6 (4.2, 7.8) | 0.069 |
| No lymph node metastasis | n = 9 | n = 20 | |
| Median TTP (95%CI), months | 6 (2.1, 8.9) | 2 (0.6, 3.4) | 0.051 |
| Median OS (95%CI), months | 17 (12.8, 21.2) | 6 (3.8, 8.2) | 0.023 |
TTP, time to progression; OS, overall survival; DEB-TACE, drug-eluting beads transarterial chemoembolization; cTACE, conventional transarterial chemoembolization.